Shots:
- BMS & Bain Capital have launched a new independent biopharma company focused on autoimmune diseases, which will be backed by $300M funding commitment led by Bain & 5 immunology assets in-licensed from BMS
- As per the deal, BMS will retain ~20% equity stake in the new company & is entitled to receive royalties & milestone payments for each in-licensed immunology asset
- The company’s pipeline will incl. afimetoran (TLR7/8 inhibitor) in P-II for SLE, BMS-986322 (TYK2 inhibitor) with PoC established in P-II trial for plaque PsO; BMS-986326 in P-I for SLE & atopic dermatitis as well as 2 biologics, BMS-986481 & BMS-986498, targeting IL18 & IL10 pathways, both set to advance to P-I trials
Ref: Bristol Myers Squibb | Image: Bristol Myers Squibb and Bain Capital | Press Release
Related News:- Bain Capital to Acquire Mitsubishi Tanabe Pharma for ~$3.3B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
